Scottsdale activity can expose a sore joint or tendon

Trail and Greenbelt walks can hurt the legs in different ways

Uneven ground and long descents make knees, ankles and heels work harder. The Greenbelt is flatter, but soreness can build during a long walk.

A sudden pop followed by weak walking needs prompt care. Get checked if you can’t raise the heel or press the foot down during a step.

An ordinary ache may ease when you shorten the distance and choose level ground. Don’t return to hills until that easier walk feels comfortable.

Golf and racquet play can make heels, hips and elbows sore

A round of golf can strain a heel, hip or elbow. Racquet play repeats hard gripping and overhead movement.

Ease back when the same movement causes sharp pain. If the ache returns, tell the clinician which swing, step or reach brings it on.

Also note whether soreness settles by morning or lasts into the next day. That timing helps the exam focus on the joint or tendon involved.

The East Mountain View Road office is the nearest listed location

Drivers from farther north may reach the office by Pima Road or Loop 101. Check current traffic and office directions before leaving.

Bring notes about the painful movement, along with an X-ray and medicine list. Expect questions about how the soreness started and which actions raise it.

Your answers keep the exam focused on the painful area. If return trips are hard, ask how often follow-up visits occur.

Ask who takes calls after a visit and what changes need attention. The office schedule should fit your travel needs as well as the care plan.

Sources

1. A clinical-recommendations review graded PRP indication by indication: good evidence for leukocyte-poor PRP in knee osteoarthritis; moderate-to-high-quality evidence for leukocyte-rich PRP in patellar tendinopathy and for PRP in plantar fasciitis; INSUFFICIENT evidence to routinely recommend PRP for rotator cuff tendinopathy, hip osteoarthritis or high ankle sprains; and demonstrated LACK of efficacy for Achilles tendinopathy, muscle injuries, acute fracture or non-union, and as a surgical augment in rotator cuff repair, Achilles repair and ACL reconstruction.

   Le ADK, Enweze L, DeBaun MR, et al. — Current Clinical Recommendations for Use of Platelet-Rich Plasma. Current Reviews in Musculoskeletal Medicine, 2018. DOI: 10.1007/s12178-018-9527-7.

2. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

3. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

4. A 12-centre randomized controlled trial of 230 patients with chronic lateral epicondylar tendinopathy compared tendon needling with leukocyte-enriched PRP against tendon needling alone. At 12 weeks there was no significant difference (55.1% versus 47.4% pain improvement; P=.163). At 24 weeks the PRP group reported 71.5% versus 56.1% pain improvement (P=.019), a 83.9% versus 68.3% success rate (P=.037), and significantly less residual elbow tenderness (29.1% versus 54.0%; P=.009). No significant complications occurred in either group.

   Mishra AK, Skrepnik NV, Edwards SG, et al. — Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. American Journal of Sports Medicine, 2014. DOI: 10.1177/0363546513494359.

5. A systematic review and meta-analysis of nine randomized trials (239 PRP patients, 240 corticosteroid patients) in chronic plantar fasciitis found statistically significant differences in VAS pain favouring PRP at 1-1.5, 3, 6 and 12 months, and in AOFAS function favouring PRP at 6 and 12 months (no difference at 1 and 3 months).

   Hurley ET, Shimozono Y, Hannon CP, et al. — Platelet-Rich Plasma Versus Corticosteroids for Plantar Fasciitis: A Systematic Review of Randomized Controlled Trials. Orthopaedic Journal of Sports Medicine, 2020. DOI: 10.1177/2325967120915704.

6. An updated meta-analysis of six randomized trials (422 patients) found no benefit of PRP over placebo for Achilles tendinopathy on VISA-A at 3 months (mean difference 1.7; 95% CI -1.8 to 5.2), 6 months (0.5; 95% CI -8.5 to 9.3) or 1 year (-7.9; 95% CI -27.3 to 11.6), nor on VAS pain at 3 months. Funnel-plot asymmetry suggested publication bias inflating apparent benefits. The authors wrote that PRP should not be used to treat Achilles tendinopathy until high-quality trials show a clear clinical benefit.

   Barreto ESR, Antunes Junior CR, Silva IC, et al. — Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials. Clinical Orthopaedics and Related Research, 2025. DOI: 10.1097/CORR.0000000000003349.